IGF1 and Obesity: Patients with obesity also have higher insulin levels, leading to increased IGF-1 in breast cancer cells, which activates the PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways that result in endocrine therapy resistance [13,46,47].